Upgrade

Greenwich LifeSciences, Inc.

GLSI

Last
$16.53
Day
+9.2%
1y
+35.4%
5y
-58.8%
52w
-55.6%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
16.71
EMA 50
17.08
EMA 200
18.68
20d high
-25.4%
5y high
-62.4%
5y range
25th
Website · United States

Positions held

Your positions

GLSI isn't in your positions.

Add it to see shares, cost, and P&L here.

Score
-24
Hold
avoid
Signal
Strong Sell
Target
$17.71
Stop
$13.00
Stop distance
21.4%
Target vs last
+7.1%

Fundamentals

Market cap$222.23MEnterprise value$213.35MTrailing P/E—Forward P/E-18.46
PEG—Price / book71.42Beta1.46Dividend yield0.00%
Revenue growth—Earnings growth—Gross margin0.0%Operating margin0.0%
Profit margin0.0%ROE-9.9%ROA-2.4%Debt / equity—
Current ratio1.54Free cash flow-$3.34MAnalyst recommendationnoneMean target$57.00
52w high$34.1052w low$7.78

Quarterly

2026-Q22026-Q12025-Q42025-Q32025-Q22025-Q1
Revenue$0.0M$0.0M$0.0M$0.0M$0.0M—
Op margin——————
Net income-$3.9M-$5.7M-$7.9M-$4.2M-$3.7M—
Gross margin——————
Gross profit——————
Operating income-$4.0M-$5.7M-$7.9M-$4.2M-$3.8M—

Yearly (6y)

2025202420232022
Revenue$0.0M$0.0M$0.0M$0.0M
Op margin————
Net income-$19.4M-$17.4M-$8.9M-$7.8M
Gross margin————
Gross profit————
Operating income-$19.4M-$17.6M-$9.3M-$8.0M
Headline scan

Headlines — watch

• [WARN · legal] Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial

News

GLSI · daily-22.3% over 13 sessions
Close EMA21 EMA50 EMA200
14.2615.8517.4319.0120.602026-092026-092026-092026-092026-102026-102026-10
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin
-$8M-$6M-$4M-$2M$0M0%5%10%2025-Q22025-Q32025-Q42026-Q12026-Q2